The full content of Annals is available to subscribers

Subscribe/Learn More  >
Original Research |

6-Mercaptopurine in the Management of Inflammatory Bowel Disease: Short- and Long-Term Toxicity

Daniel H. Present, MD; Stephen J. Meltzer, MD; Michael P. Krumholz, MD; Anita Wolke, MD; and Burton I. Korelitz, MD
[+] Article, Author, and Disclosure Information

Requests for Reprints: Daniel H. Present, MD, 12 East 86th Street, New York, NY 10028.

Current Author Addresses: Dr. Present: 12 East 86th Street, New York, NY 10028.

Dr. Meltzer: Unviversity of Maryland Hospital, 22 South Greene Street, Baltimore, MD 21201.

Dr. Krumholz: 870 Park Avenue, New York, NY 10021.

Dr. Wolke: 1830 Town Center Parkway, Suite 405, Reston, VA 22090.

Dr. Korelitz: 45 East 85th Street, New York, NY 10028.

©1989 American College of PhysiciansAmerican College of Physicians

Ann Intern Med. 1989;111(8):641-649. doi:10.7326/0003-4819-111-8-641
Text Size: A A A

We assess toxicity related to 6-mercaptopurine in the treatment of inflammatory bowel disease by reporting our experience with 396 patients (120 patients with ulcerative colitis, 276 with Crohn disease) observed over 18 years. Follow-up data for a mean period of 60.3 months were obtained for 90% of the patients. Toxicity directly induced by 6-mercaptopurine included pancreatitis in 13 patients (3.3%), bone marrow depression in 8 (2%), allergic reactions in 8 (2%), and drug hepatitis in 1 (0.3%). These complications were reversible in all cases with no mortality. Most cases of marrow depression occurred earlier in our experience, when the initial drug doses used were higher. Infectious complications were seen in 29 patients (7.4%), of which 7 (1.8%) were severe, including one instance of herpes zoster encephalitis. All infections were reversible with no deaths. Twelve neoplasms (3.1%) were observed, but only 1 (0.3%), a diffuse histiocytic lymphoma of the brain, had a probable association with the use of 6-mercaptopurine. Our data, showing a low incidence of toxicity in 396 patients, coupled with the previously demonstrated efficacy of 6-mercaptopurine in the treatment of inflammatory bowel disease, indicate that the drug is a reasonable alternative in the management of patients with intractable inflammatory bowel disease.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.